NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis $1.45 +0.01 (+0.69%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 05/22/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About INmune Bio Stock (NASDAQ:INMB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get INmune Bio alerts:Sign Up Key Stats Today's Range$1.44▼$1.5050-Day Range$1.12▼$1.6852-Week Range$1.09▼$11.64Volume170,441 shsAverage Volume481,902 shsMarket Capitalization$38.54 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview INmune Bio, Inc. is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions. The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions. XPro1595 is currently being evaluated in early-stage clinical trials for indications including Alzheimer’s disease and various solid tumors. Complementing this, INmune Bio is developing NB-01, an innate immune activator aimed at stimulating gamma-delta T cells through toll-like receptor 2 (TLR2) agonism, with potential applications in oncology and infectious diseases. Founded in 2014 by a team of immunology and biotechnology veterans, INmune Bio advanced to a public listing on the NASDAQ market in 2018. The company supports a diverse pipeline spanning preclinical and Phase 1 studies, leveraging collaborations with academic institutions and clinical research organizations. While headquartered in the United States, INmune Bio’s programs involve clinical sites across North America, reflecting its commitment to addressing global therapeutic needs. The leadership team comprises professionals with extensive experience in drug discovery, clinical development and commercial strategy within the biopharmaceutical industry. Under their guidance, the company continues to expand its platform capabilities, seeking to translate innate immune modulation into novel treatments for patients with limited options.AI Generated. May Contain Errors. Read More INmune Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreINMB MarketRank™: INmune Bio scored higher than 28% of companies evaluated by MarketBeat, and ranked 756th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingINmune Bio has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 strong buy rating, 1 buy rating, 2 hold ratings, and 2 sell ratings.Upside PotentialINmune Bio has a consensus price target of $8.00, representing about 451.7% upside from its current price of $1.45.Amount of Analyst CoverageINmune Bio has only been the subject of 1 research reports in the past 90 days.Read more about INmune Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of INmune Bio is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INmune Bio is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about INmune Bio's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.86% of the float of INmune Bio has been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 17.79, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently increased by 5.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.30 News SentimentINmune Bio has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for INmune Bio this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for INMB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added INmune Bio to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have not sold or bought any company stock.Percentage Held by Insiders21.00% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.72% of the stock of INmune Bio is held by institutions.Read more about INmune Bio's insider trading history. Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INMB Stock News HeadlinesINmune Bio, Inc. (NASDAQ:INMB) Given Average Rating of "Hold" by BrokeragesMay 22 at 4:43 AM | americanbankingnews.comINMB Share News TodayMay 19, 2026 | uk.investing.comOne algorithm, 17 years, nearly 2,000% total returnsA physicist in Dublin claims his AI algorithm has beaten the market for 17 consecutive years - with nearly 2,000% total returns and only one losing year across two decades of crises. Porter Stansberry flew to Ireland to investigate the claim firsthand. The result is a new investigative documentary called 'Investigating Project Prophet,' available to stream now at no cost.May 24 at 1:00 AM | Porter & Company (Ad)INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ PlatformMay 15, 2026 | globenewswire.comINmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's DiseaseMay 14, 2026 | globenewswire.comINmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection PointMay 13, 2026 | globenewswire.comINmune Bio, Inc. (NASDAQ:INMB) Q1 2026 Earnings Call TranscriptMay 10, 2026 | insidermonkey.comINmune Bio (INMB) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comSee More Headlines INMB Stock Analysis - Frequently Asked Questions How have INMB shares performed this year? INmune Bio's stock was trading at $1.56 at the beginning of 2026. Since then, INMB stock has decreased by 7.1% and is now trading at $1.45. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.05. Read the conference call transcript. When did INmune Bio IPO? INmune Bio (INMB) raised $20 million in an initial public offering on the week of February 4th 2019. The company issued 2,500,000 shares at $8.00 per share. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that INmune Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX). Company Calendar Last Earnings5/07/2026Today5/24/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (20m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 INMB's financial health is in the Red zone, according to TradeSmith. INMB has been in this zone for over 20 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INMB CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for INmune Bio$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+451.7%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.93 million Net MarginsN/A Pretax Margin-91,866.00% Return on Equity-103.03% Return on Assets-77.66% Debt Debt-to-Equity RatioN/A Current Ratio4.24 Quick Ratio4.24 Sales & Book Value Annual Sales$50 thousand Price / Sales770.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book1.96Miscellaneous Outstanding Shares26,580,000Free Float21,002,000Market Cap$38.54 million OptionableOptionable Beta1.04 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:INMB) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
